arrow
B

Brian Calimlim

Medical University of South Carolina
H指数:25
被引数:2,337

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)

在Dupilumab治疗反应不足后,成人及青少年中重度特应性皮炎患者从Dupilumab转换为Upadacitinib:来自Phase 3b/4研究(LEVEL UP)第二期试验的疗效与安全性结果

2026-01-140
OAAI
Racial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States

美国特应性皮炎患者获得先进疗法中的种族和族裔差异

2026-01-010
PRE
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks

乌帕替尼(Upadacitinib)治疗中重度特应性皮炎的疗效与安全性:第3期随机临床试验结果(为期140周)

2025-09-030
OAAI
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

通过乌帕替尼实现中重度特应性皮炎的最佳治疗目标和最低疾病活动度:第3期研究(Measure Up 1和2)的综合分析

2025-07-140
OA
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study

Upadacitinib与Dupilumab治疗四个身体区域中重度特应性皮炎的疗效和安全性: 来自head Up研究的分析

2024-10-300
OA
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)
2024-10-231
OA
Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies

upadacitinib治疗青少年和成人中度至重度特应性皮炎患者的体征、症状和生活质量持续改善140周: 3期Measure Up 1和Measure Up 2研究的综合结果

2024-08-080
PRE
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

乌帕替尼可快速改善特应性皮炎患者的患者报告结局:3期临床试验(Measure Up 1和2)第16周结果

2024-05-021
PRE
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
2024-03-251
OAAI
Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study

upadacitinib与dupilumab对中度至重度特应性皮炎的疗效: Heads Up研究中瘙痒反应状态所花费的时间分析

2024-02-070
PRE
Real-world use and effectiveness of upadacitinib in adults and adolescents with atopic dermatitis: preliminary analysis of the real-world multicountry AD-VISE study

upadacitinib在成人和青少年特应性皮炎中的真实世界使用和有效性: 真实世界多国AD-VISE研究的初步分析

2024-02-070
PRE
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results

upadacitinib治疗青少年和成人中度至重度特应性皮炎140周的疗效和安全性: 3期随机临床试验结果

2024-02-070
PRE